{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:17:41Z","timestamp":1787771861421,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Androgen-deprivation therapy is the mainstay of treatment for the management of advanced prostate carcinoma till transition to castration-resistant prostate carcinoma (CRPC). Recently, adrenal and intratumoral synthesis of androgens has been found to be the major cause for CRPC. Abiraterone acetate is an orally active, potent and selective inhibitor of 17 a hydroxylase and c 17, 20 lyase, which acts by decreasing the\n                      <jats:italic toggle=\"yes\">de novo<\/jats:italic>\n                      production of androgens with no rise in steroids downstream. Multiple randomized trials have shown significant improvement of &gt;50% decline in prostate-specific antigen (PSA) and time to PSA progression (TTPP) with abiraterone acetate 1000 mg per day in chemotherapy\/ketoconazole treated and naive CRPC patients producing reversible and manageable adverse effects due to mineralocorticoid excess. This article reviews the available evidence on efficacy and safety of this drug in CRPC. Searches of Pubmed, Cochrane database, Medscape, Google and clinicaltrial.org were made for terms like CRPC and abiraterone.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0022-3859.101400","type":"journal-article","created":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T20:40:02Z","timestamp":1348692002000},"page":"203-206","source":"Crossref","is-referenced-by-count":1,"title":["Abiraterone acetate"],"prefix":"10.4103","volume":"58","author":[{"given":"R","family":"Nandha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20240205","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4065\/mcp.2009.0442","article-title":"New Developments in the Medical Management of Prostate Cancer","volume":"85","author":"Kohli","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"R2-9-20240205","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdq639","article-title":"Novel approaches and future directions in castration-resistant prostate cancer","volume":"22","author":"Nabhan","year":"2011","journal-title":"Ann Oncol"},{"key":"R4-9-20240205","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/ERC-10-0187","article-title":"An update on androgen deprivation therapy for prostate cancer","volume":"17","author":"Sharifi","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"R5-9-20240205","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"R6-9-20240205","doi-asserted-by":"crossref","first-page":"211","DOI":"10.6004\/jnccn.2010.0014","article-title":"Adverse effects of androgen deprivation therapy: Defining the problem and promoting health among men with prostate cancer","volume":"8","author":"Saylor","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"R7-9-20240205","first-page":"671","article-title":"Abiraterone and newer antiandrogen compounds for castrate resistant metastatic prostate cancer","volume":"100","author":"Dawson","year":"2009","journal-title":"Br J Cancer"},{"key":"R8-9-20240205","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1200\/JCO.2009.25.3781","article-title":"Castration-resistant prostate cancer: Hormone therapy redux","volume":"28","author":"Tolcher","year":"2010","journal-title":"J Clin Oncol"},{"key":"R9-9-20240205","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2011.117","article-title":"The changing therapeutic landscape of castration-resistant prostate cancer","volume":"8","author":"Yap","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"R10-9-20240205","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resisitant prostate cancer","volume":"28","author":"Danila","year":"2010","journal-title":"J Clin Oncol"},{"key":"R11-9-20240205","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased Expression Of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res"},{"key":"R12-9-20240205","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9440(10)63112-4","article-title":"Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance","volume":"164","author":"Holzbeierlein","year":"2004","journal-title":"Am J Pathol"},{"key":"R13-9-20240205","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1078-0432.CCR-1146-03","article-title":"The Androgen Axis in Recurrent Prostate Cancer","volume":"10","author":"Mohler","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R14-9-20240205","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism in Castration -Resistant Tumor Growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res"},{"key":"R15-9-20240205","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.coph.2008.06.004","article-title":"Targeting CYP17: Established and novel approaches in prostate cancer","volume":"8","author":"Yap","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"R16-9-20240205","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R17-9-20240205","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","article-title":"Hormonal impact of the 17alpha-hydroxylase\/C (17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer","volume":"90","author":"O'Donnell","year":"2004","journal-title":"Br J Cancer"},{"key":"R18-9-20240205","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2217\/fon.10.48","article-title":"Abiraterone acetate: A promising drug for the treatment of castration-resistant prostate cancer","volume":"6","author":"Agarwal","year":"2010","journal-title":"Future Oncol"},{"key":"R19-9-20240205","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1200\/JCO.2011.37.1617","article-title":"Flushing Oral Oncology Drugs Down the Toilet","volume":"29","author":"Ratain","year":"2011","journal-title":"J Clin Oncol"},{"key":"R20-9-20240205","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1158\/1078-0432.CCR-10-1857","article-title":"Food and oral antineoplastics: More than meets the eye","volume":"16","author":"Jain","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R21-9-20240205","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"R22-9-20240205","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1200\/JCO.2009.24.1281","article-title":"Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy","volume":"28","author":"Ryan","year":"2010","journal-title":"J Clin Oncol"},{"key":"R23-9-20240205","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J Clin Oncol"},{"key":"R24-9-20240205","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","article-title":"Significant and sustained antitumour activity in post-docetaxel, castration-resisitant prostaste cancer with the CYP17 inhibitor abiraterone acetate","volume":"28","author":"Reid","year":"2010","journal-title":"J Clin Oncol"},{"key":"R25-9-20240205","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-201258030-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:18:10Z","timestamp":1787768290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-201258030-00009"}},"subtitle":["A novel drug for castration-resistant prostate carcinoma"],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.101400","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2012]]}}}